Person:
KHAN, IMRAN

Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
IMRAN
Last Name
KHAN
Name
Email Address
Birth Date

Filters

2020 - 20213
Reset filters

Settings

Author: Khan, Imran × Has files: true ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Can COVID-19 induce glioma tumorogenesis through binding cell receptors?
    (2020-06-01T00:00:00Z) Khan, Imran; KHAN, IMRAN
    The outbreak of Novel Coronavirus 2019 (COVID-19) represents a global threat to the public healthcare. The viral spike (S) glycoprotein is the key molecule for viral entry through interaction with angiotensin converting enzyme 2 (ACE2) receptor molecules present on the cell membranes. Moreover, it has been established that COVID-19 interacts and infects brain cells in humans via ACE2. Therefore in the light of these known facts we hypothesized that viral S protein molecule may bind to the other overexpressed receptor molecules in glioma cells and may play some role in glioma tumorogenesis. Thus we leverage docking analysis (HEX and Z-DOCK) between viral S protein and epidermal growth factor receptors (EGFR), vascular endothelial growth factor receptors (VEGFR) and hepatocyte growth factor receptors (HGFR/c-MET) to investigate the oncogenic potential of COVID-19. Our findings suggested higher affinity of Viral S protein towards EGFR and VEGFR. Although, the data presented is preliminary and need to be validated further via molecular dynamics studies, however it paves platform to instigate further investigations on this aspect considering the aftermath of COVID-19 pandemic in oncogenic perspective.
  • Thumbnail Image
    PublicationOpen Access
    Therapeutic Phytochemical Actives for Potential Control of SARS-CoV-2
    (2021-05-01T00:00:00Z) Khan, Imran; KHAN, IMRAN
  • Thumbnail Image
    PublicationOpen Access
    Targeting Glioblastoma: The Current State of Different Therapeutic Approaches.
    (2021-01-13T00:00:00Z) Khan, Imran; Elbasan, Elif Burce; Mahfooz, Sadaf; Karacam, Busra; Oztanir, MUSTAFA NAMIK; Hatiboglu, Mustafa Aziz; KHAN, IMRAN; ELBASAN, ELİF BURÇE; KARAÇAM, BÜŞRA; ÖZTANIR, MUSTAFA NAMIK; HATİBOĞLU, MUSTAFA AZİZ
    Background: Glioma is the primary cancer of the central nervous system in adults. Among gliomas, glioblastoma is the most deadly and aggressive form, with an average life span of 1 to 2 years. Despite implementing the rigorous standard care involving maximal surgical removal followed by concomitant radiation and chemotherapy, the patient prognosis remains poor. Due to the infiltrative nature of glioblastoma, chemo- and radio-resistance behavior of these tumors and lack of potent chemotherapeutic drugs, treatment of glioblastoma is still a big challenge. Objective: The goal of the present review is to shed some light on the present state of novel strategies, including molecular therapies, immunotherapies, nanotechnology and combination therapies for patients with glioblastoma. Methods: Peer-reviewed literature was retrieved via Embase, Ovid, PubMed and Google Scholar till the year 2020. Conclusion: Insufficient effect of chemotherapies for glioblastoma is more likely because of different drug resistance mechanisms and intrinsically complex pathological characteristics. Therefore, more advancement in various therapeutic approaches such as antitumor immune response, targeting growth regulatory and drug resistance pathways, enhancing drug delivery and drug carrier systems are required in order to establish an effective treatment approach for patients with glioblastoma.